Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Public advisory - Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infection


OTTAWA, ON, July 7, 2023 /CNW/ -

Summary
Images

Rhinaris Nasal Mist 30 mL (CNW Group/Health Canada)

Rhinaris Nasal Mist 30 mL (CNW Group/Health Canada)

Affected products

Product

DIN

Lot

Expiry date

UPC

Rhinaris Nasal Mist 30 mL

02354551

230391A

31-05-2025

5760622302

Issue

The Pendopharm Division of Pharmascience Inc. is recalling one lot of Rhinaris Nasal Mist due to the risk of microbial growth. Using a product contaminated with microbes may lead to rhinosinusitis (a sinus infection). Children, pregnant people, seniors and people with weaker immune systems may be more susceptible to infection or complications from microbial contamination.

Rhinaris Nasal Mist is an over-the-counter drug used to moisturize and lubricate dry nasal passages  in adults and children at least two years of age. 

The company's testing showed that the preservative in the product may not be as effective as expected, which could lead to an increased risk of growth of microbes such as molds or bacteria over time if they are introduced into the product.

Although rare, rhinosinusitis can lead to more serious complications, such as nasal abscesses (a collection of pus), cellulitis (skin infection) or meningitis (infection and inflammation of the fluid and membranes surrounding the brain and spinal cord).

While the growth of other microbes may be possible, the testing showed that the preservative may not prevent the growth of a specific type of bacteria called Pseudomonas aeruginosa if it is introduced into the product. For someone whose immune system has been weakened by other serious conditions, especially cystic fibrosis, HIV/AIDS, severe lung disease, cancer, diabetes, or burns, Pseudomonas aeruginosa can cause serious infections including pneumonia, bone infections, urinary tract infections, gastrointestinal infections, meningitis, and blood infections.

What you should do

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 07:50
Tilray Brands, Inc. ("Tilray Brands" or the "Company") , a leading global lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, announced today that it has filed a prospectus...

at 07:30
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown Magnificent Mile on June 21?22, 2024. This biennial...

at 07:30
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF1, used...

at 07:30
The American Trucking Associations is calling attention to the negative consequences for highway safety and safety-sensitive industries that could result from the U.S. Drug Enforcement Administration's proposal to reschedule marijuana from a Schedule...

at 07:30
-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)-    Data to be presented from...

at 07:28
We are advised by OsteoStrong that journalists and other readers should disregard the news release, OsteoStrong Celebrates Success and Innovation at 11th Annual Global Franchise Owner Convention, issued May 9, 2024 over PR Newswire. SOURCE...



News published on and distributed by: